Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential

Current Addiction Reports

Volumn 1, Issue 2, 2014, Pages 129-136

  Tai, Sherrica ^a   Fantegrossi, William E ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cannabis; CB1 receptors; Psychoactive effects; SCBs; Synthetic cannabinoids; THC

Indexed keywords

EID: 84938361781     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-014-0014-y     Document Type: Review

References (65)

1. Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD; 2013.
2. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. The rise in teen marijuana use stalls, synthetic marijuana use levels, and use of 'bath salts' is very low. University of Michigan News Service: Ann Arbor, MI. Retrieved 09/24/2013 from http://www.monitoringthefuture.org, 2012.
3. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, et al. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013. 233(1-3): p. 416-22. This study details efforts to track the compositions of commercial SCB products in the state of Arkansas over a three-year period during which several major state and federal legislative changes aimed at controling the proliferation of these substances were enacted. The major psychoactive constituents on commercial SCB products are described, as are the effects of legislation on drug availability.
4. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44(5):832–7.
5. Drug Enforcement Administration. Schedules of controlled substances: temporary placement of five synthetic cannabinoids into Schedule I. Microgram Bulletin, 2011. 44(3): 21-30.
6. Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, et al. Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Leg Med. 2014;128:59–64.
7. Drug Enforcement Administration. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order. Fed Regist. 2013. 78(95): 28735-9.
8. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, et al. Spice: a never ending story? Forensic Sci Int. 2009;191(1–3):58–63.
9. Piggee C. Investigating a not-so-natural high. Anal Chem. 2009;81(9):3205–7.
10. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011;117(2–3):152–7.
11. Forrester MB. Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr Emerg Care. 2012;28(10):985–9.
12. Pant S, Deshmukh A, Dholaria B, Kaur V, Ramavaram S, Ukor M, et al. Spicy seizure. Am J Med Sci. 2012;344(1):67–8.
13. Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol. 2012;8(1):62–4.
14. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012. 21(4): p. 320-6. Several cases of SCB use among THC-dependent subjects are described. The fact that SCBs prevent or alleviate THC withdrawal implies that these drugs are likely to share a common site and mechanism of action.
15. Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013;7(4):296–8.
16. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int. 2009;106(27):464–7.
17. American Association of Poison Control Centers. Synthetic Marijuana Data. Retrieved 02/10/2013 from http://www.aapcc.org/alerts/synthetic-marijuana/, 2013.
18. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161–202.
19. Montero C, Campillo NE, Goya P, Páez JA. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. Eur J Med Chem. 2005;40(1):75–83.
20. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005;106(2):133–45.
21. Tucci SA, Halford JC, Harrold JA, Kirkham TC. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem. 2006;13(22):2669–80.
22. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.
23. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Hezode C, et al. The endocannabinoid system as a novel target for the treatment of liver fibrosis. Pathol Biol. 2008;56(1):36–8.
24. Garcia-Gutierrez MS, Garcia-Bueno B, Zoppi S, Leza JC, Manzanares J. Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol. 2012;165(4):951–64.
25. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, et al. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci. 2011;14(9):1160–6.
26. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett. 2004;25(1–2):14–23.
27. Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans Roy Soc Lond B, Biol Sci. 2012;367(1607):3216–28.
28. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans Roy Soc Lond B, Biol Sci. 2012. 367(1607): p. 3353-63.
29. Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. Chem Phys Lipids. 2002;121(1–2):3–19.
30. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther. 1992;260(1):201–9.
31. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988;247(3):1046–51.
32. Fan F, Compton DR, Ward S, Melvin L, Martin BR. Development of cross-tolerance between delta-9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther. 1994;271(3):1383–90.
33. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012;83(7):952–61.
34. Wiebelhaus JM, Poklis JL, Poklis A, Vann RE, Lichtman AH, Wise LE. Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice. Drug Alcohol Depend. 2012. 126(3): 316-23. This is the first demonstration that cannabimimetic effects of a commercial SCB product are induced in mice after "smoking." All of the in vivo endpoints of the cannabinoid tetrad are utilized, and these effects are blunted in mice previously administered a CB1 antagonist.
35. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011. 6(7): e21917. This paper assesses CB1 receptor affinity and efficacy for a number of hydroxylated Phase I metabolistes of the SCB JWH-018. In vitro, it is shown that many of these metabolites retain high affinity for the CB1 receptor, and exhibit a range of efficacies from full agonism to antagonism. In vivo, one of these metabolites elicits hypothermic effects via activation of CB1 receptors. The formation of these active metabolites will likely differ among individuals as a function of CPY450 polymorphisms, and may be a mechanism for toxicity in some individuals.
36. Wiley JL, Huffman JW, Balster RL, Martin BR. Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend. 1995;40(1):81–6.
37. Jarbe TU, Lamb RJ, Lin S, Makriyannis A. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl). 2001. 156(4): 369-80.
38. Balster RL, Prescott WR. Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev. 1992;16(1):55–62.
39. Jarbe TU, Deng H, Vadivel SK, Makriyannis A. Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Delta(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol. 2011. 22(5-6): 498-507. The experiments described in this report highlight the utility of the drug discrimination procedure in the study of emerging SCBs.
40. Jarbe TU, Vadivel SK, Makriyannis A. Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology (Berl). 2010;208(1):87–98.
41. Ginsburg BC, Schulze DR, Hruba L, McMahon LR. JWH-018 and JWH-073: Delta(9)-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther. 2012;340(1):37–45.
42. Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF. Cannabinoids in disguise: Delta(9)-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology. 2013;75:145–54.
43. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012;40(11):2174–84.
44. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 2003;169(2):135–40.
45. Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci. 2000;3(11):1073–4.
46. Fattore L, Cossu G, Martellotta CM, Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl). 2001;156(4):410–6.
47. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience. 1998;85(2):327–30.
48. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 2001;21(14):5344–50.
49. Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav. 2005;81(2):285–99.
50. Lepore M, Vorel SR, Lowinson J, Gardner EL. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci. 1995;56(23–24):2073–80.
51. Castane A, Robledo P, Matifas A, Kieffer BL, Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci. 2003;17(1):155–9.
52. Valjent E, Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl). 2000;147(4):436–8.
53. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol. 2002;135(2):564–78.
54. Hyatt WS, Fantegrossi WE. Delta-9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/”Spice” constituent JWH-018 in mice. Behav Pharmacol. 2014. in press.
55. Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Neurosci. 2004;506(1):63–9.
56. Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience. 2001;104(4):923–6.
57. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585–614.
58. Dewey WL, Peng TC, Harris LS. The effect of 1-trans-delta 9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur J Pharmacol. 1970;12(3):382–4.
59. Pertwee RG, Stevenson LA, Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol. 1993;110(4):1483–90.
60. Hruba L, Ginsburg BC, McMahon LR. Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Delta(9)-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther. 2012;342(3):843–9.
61. Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxaz inyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther. 2002;303(1):36–44.
62. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
63. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J, et al. Quantifying the clinical significance of cannabis withdrawal. PLoS One. 2012;7(9):e44864.
64. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119(1–2):123–9.
65. Aceto MD, Scates SM, Martin BB. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol. 2001;416(1–2):75–81.